These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 7545355)
1. Monoclonal antibody-based immunoassay for evaluation of lipoprotein oxidation. Preobrazhensky S; Trakht I; Chestkov V; Wentz M Anal Biochem; 1995 May; 227(1):225-34. PubMed ID: 7545355 [TBL] [Abstract][Full Text] [Related]
2. Involvement of the macrophage low density lipoprotein receptor-binding domains in the uptake of oxidized low density lipoprotein. Keidar S; Brook GJ; Rosenblat M; Fuhrman B; Dankner G; Aviram M Arterioscler Thromb; 1992 Apr; 12(4):484-93. PubMed ID: 1373074 [TBL] [Abstract][Full Text] [Related]
3. Melatonin protects LDL from oxidation but does not prevent the apolipoprotein derivatization. Pieri C; Marra M; Gáspár R; Damjanovich S Biochem Biophys Res Commun; 1996 May; 222(2):256-60. PubMed ID: 8670192 [TBL] [Abstract][Full Text] [Related]
4. Direct evidence for apo B-100-mediated copper reduction: studies with purified apo B-100 and detection of tryptophanyl radicals. Batthyány C; Santos CX; Botti H; Cerveñansky C; Radi R; Augusto O; Rubbo H Arch Biochem Biophys; 2000 Dec; 384(2):335-40. PubMed ID: 11368321 [TBL] [Abstract][Full Text] [Related]
5. Protective effects of leaf extract of Zanthoxylum ailanthoides on oxidation of low-density lipoprotein and accumulation of lipid in differentiated THP-1 cells. Chu CY; Lee HJ; Chu CY; Yin YF; Tseng TH Food Chem Toxicol; 2009 Jun; 47(6):1265-71. PubMed ID: 19254748 [TBL] [Abstract][Full Text] [Related]
6. Characterization of a specific monoclonal antibody 9F5-3a and the development of assay system for oxidized HDL. Nakajima T; Sakagishi Y; Katahira T; Nagata A; Kuwae T; Nakamura H; Inoue I; Takahashi K; Katayama S; Komoda T Biochem Biophys Res Commun; 1995 Dec; 217(2):407-11. PubMed ID: 7503715 [TBL] [Abstract][Full Text] [Related]
7. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions. Moguilevsky N; Zouaoui Boudjeltia K; Babar S; Delrée P; Legssyer I; Carpentier Y; Vanhaeverbeek M; Ducobu J Biochem Biophys Res Commun; 2004 Oct; 323(4):1223-8. PubMed ID: 15451427 [TBL] [Abstract][Full Text] [Related]
9. Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation. Miller YI; Felikman Y; Shaklai N Arch Biochem Biophys; 1996 Feb; 326(2):252-60. PubMed ID: 8611031 [TBL] [Abstract][Full Text] [Related]
10. Oxidative and malondialdehyde modification of low-density lipoprotein: a comparative study. Chen Y; Zhou M; Liu S; Ding Z; Lou N; Pang Z; Wan J Br J Biomed Sci; 1997 Sep; 54(3):159-65. PubMed ID: 9499592 [TBL] [Abstract][Full Text] [Related]
11. The mechanism of apolipoprotein B-100 thiol depletion during oxidative modification of low-density lipoprotein. Ferguson E; Singh RJ; Hogg N; Kalyanaraman B Arch Biochem Biophys; 1997 May; 341(2):287-94. PubMed ID: 9169017 [TBL] [Abstract][Full Text] [Related]
12. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Virella G; Koskinen S; Krings G; Onorato JM; Thorpe SR; Lopes-Virella M Clin Immunol; 2000 May; 95(2):135-44. PubMed ID: 10779407 [TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein B-bound lipids as a marker for evaluation of low density lipoprotein oxidation in vivo. Tertov VV; Kaplun VV; Dvoryantsev SN; Orekhov AN Biochem Biophys Res Commun; 1995 Sep; 214(2):608-13. PubMed ID: 7677772 [TBL] [Abstract][Full Text] [Related]
14. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Palinski W; Ylä-Herttuala S; Rosenfeld ME; Butler SW; Socher SA; Parthasarathy S; Curtiss LK; Witztum JL Arteriosclerosis; 1990; 10(3):325-35. PubMed ID: 1693068 [TBL] [Abstract][Full Text] [Related]
15. Low density lipoprotein oxidation and atherogenesis: from experimental models to clinical studies. Napoli C G Ital Cardiol; 1997 Dec; 27(12):1302-14. PubMed ID: 9470066 [TBL] [Abstract][Full Text] [Related]
16. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281 [TBL] [Abstract][Full Text] [Related]
17. Immunoreactivity of apo B towards monoclonal antibodies that inhibit the LDL-receptor interaction: effects of LDL oxidation. Negri S; Roma P; Fogliatto R; Uboldi P; Marcovina S; Catapano AL Atherosclerosis; 1993 Jun; 101(1):37-41. PubMed ID: 7692863 [TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity of apolipoprotein B-100 and binding to LDL-receptor of phospholipase A2-treated low density lipoproteins. Korotaeva AA; Golovanova NK; Vlasik TN; Yanushevskaya EV; Tsibulsky VP; Yakushkin VV; Tvorogova MG; Morozkin AD; Prokazova NV Biochemistry (Mosc); 1998 Dec; 63(12):1430-7. PubMed ID: 9916162 [TBL] [Abstract][Full Text] [Related]
19. Resistance to LDL oxidative modifications of an N-terminal apolipoprotein B epitope. Gandjini H; Gambert P; Athias A; Lallemant C Atherosclerosis; 1991 Jul; 89(1):83-93. PubMed ID: 1722977 [TBL] [Abstract][Full Text] [Related]
20. Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein. Valentinova NV; Gu ZW; Yang M; Yanushevskaya EV; Antonov IV; Guyton JR; Smith CV; Gotto AM; Yang CY Biol Chem Hoppe Seyler; 1994 Oct; 375(10):651-8. PubMed ID: 7534086 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]